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Restricted mean models for transplant
benefit and urgency
Fang Xiang and Susan Murray*†
The US lung allocation policy estimates each individual’s urgency and transplant benefit in defining a lung allo-
cation score (LAS). Transplant benefit, as defined by the Organ Procurement and Transplantation Network
Thoracic Committee, is the days of life gained over the following year if transplanted versus not transplanted.
Urgency is measured by days of life during the next year without transplant. In both definitions, accurate estima-
tion of wait list days lived, or a wait list restricted mean lifetime, is required. Risk factors are available to estimate
patient urgency when listed, with more urgent patients removed from the wait list upon death or transplant. As
a patient progresses, priority for transplant (censoring) changes accordingly. Therefore, it is crucial to adjust
for dependent censoring in modeling days of life. We develop a model for the restricted mean as a function of
covariates, by using pseudo-observations that account for dependent censoring linked to a series of longitudinal
measures (LAS). Simulation results show that our method performs well in situations comparable with the LAS
setting. Applying wait list and post-transplant model results that account for dependent censoring to wait list
patients, we obtain estimates of transplant benefit that are larger for many of the more urgent patients in need
of transplant. The difference in LAS for an individual, when properly accounting for dependent censoring, has
high impact on the priority and timing of an organ offer for these patients. Copyright © 2012 John Wiley &
Sons, Ltd.
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1. Introduction
For the statistical aspects of lung transplant candidate data to be appreciated, some background is
required. To get a lung transplant in the USA, candidates register with the Organ Procurement and
Transplantation Network (OPTN) to obtain placement on a lung waiting list. When these transplants
were infrequent, a first come, first served policy seemed equitable to those waiting for transplant. But
as the demand increased, so did the average waiting time to transplant, and an increasing number of
end-stage lung disease patients died while waiting for an organ offer. Published in 1998 and enacted in
2000, a Final Rule, crafted by the Health Resources and Services Administration of the US Department
of Health and Human Services, dictated, among other things, that a more equitable organ allocation
algorithm needed to be created and maintained based on objective medical data [1].
In the case of patients waiting for a lung transplant, a statistical algorithm (lung allocation score or
LAS) for ranking patients was implemented on May 4, 2005 [2]. The LAS includes measures of the net
benefit of the transplant to the candidate as well as the candidate’s clinical urgency over the upcoming
year. The measure for net transplant benefit is calculated by subtracting the patient’s estimated number
of days lived on the waiting list without a transplant over the next year (i.e., transplant urgency) from
the estimated number of days lived during the first year following transplantation (i.e., post-transplant
survival measure). This is an individual measure of transplant benefit rather than a collective measure of
transplant benefit that is sometimes obtained through the use of a time-dependent covariate for transplant,
as in analyses carried out for the original Stanford Heart Transplant study [3].
Figure 1 shows the estimated patient-specific urgency by anticipated transplant benefit for a group of
lung candidates actively listed between September 1, 2006 and September 30, 2008. It was recognized
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Figure 1. Scatterplots of estimated days lived in a year on the waiting list versus estimated 1-year transplant
benefit (transplant benefit D estimated post-transplant days lived in next year minus estimated waiting list days
lived in a year without transplant) at the time of listing for n D 3701 patients. Allocation follows according to the
movement of the diagonal line from the top left to the bottom right. Patients marked as 1, 2, and 3 are the first
patients to be offered a lung transplant.
that ordering patients based on urgency alone, that is, from left to right in Figure 1, might prioritize
patients with little or no transplant benefit, whereas ordering patients solely based on higher benefit, that
is, from top to bottom of Figure 1, would likely result in many deaths of urgent patients who would not
live until an organ offer. In the end, a compromise was reached so that both benefit and urgency were
taken into consideration, that is, allocation according to the diagonal line moving from top left to bottom
right of Figure 1. The LAS takes the difference between the net transplant benefit and the transplant
urgency, with the final score normalized to produce a range from 0 to 100.
Estimates for both urgency and benefit depend on accurate estimation of wait list days lived during
the year following listing. Patients’ risk factors measured at listing include diagnosis, age, body mass
index (BMI), diabetes, assistance with activities of daily living (ADL), 6-min walk distance (6MWD),
forced vital capacity (FVC), oxygen (O2) requirement at rest, pulmonary artery (PA) systolic pressure,
partial pressure of carbon dioxide in the blood (PCO2), continuous mechanical ventilation, creatinine,
and cardiac index. For estimating days lived in the year following transplant, risk factors used in the
LAS include diagnosis, age, assistance with ADL, 6MWD, FVC, continuous mechanical ventilation,
cardiac index, O2 requirement at rest, and creatinine. More details on statistical methodology will be
given shortly.
The LAS has been largely successful since its implementation. The number of deaths on the wait-
ing list and the waiting time for transplant have decreased. As opposed to 512 wait list deaths in 2004,
there were only 266 deaths in 2008, in spite of more urgent patients being listed in 2008 [4]. Listing
behavior of end-stage lung patients has changed dramatically since the implementation of LAS. With no
advantage to accruing waiting time in the new allocation score, the number of patients actively listed for
transplant decreased from 2163 candidates at the end of 2004 to 1089 patients at the end of 2008 [4].
That is, patients not yet ready to accept an organ offer began to remove themselves from the active candi-
date pool and delay entering the pool until further progression of disease. As a consequence, the median
waiting time has dropped from 792 days in 2004 to 200 days or less after the LAS was used [4]. As
successful as the LAS has been, national policy dictates that the algorithm must be continually updated
to reflect more recent cohorts of patients, and this is occurring right now in a post-LAS implementation
cohort.
The estimated number of days lived during a year in the calculation of LAS is sometimes called
the restricted mean life. When estimated nonparametrically, under independent censoring, it is typically
defined using the area under a Kaplan–Meier (KM) survival curve [5] for the period of interest (0 to
1 year). In the original development of the LAS, a Cox proportional hazards (PH) model [6] was used to
estimate each individual’s survival curve, and the area under the first year of the survival curve was used
to estimate the restricted mean life. We feel that a more appropriate model would target the restricted
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mean more directly, rather than modeling the hazard ratio. Not only would regression parameters be
more directly linked to the restricted mean of interest, but also increased transparency of how scores for
the LAS are produced would be welcomed by patients and physicians following allocation scores.
Andersen et al. [7] introduced one modeling strategy for the restricted mean. First, they generated
pseudo-observations (POs) that have the same conditional mean of interest for regression modeling as
the original individual level data. The advantage of creating POs in the first modeling step is that they
can be modeled using traditional uncensored linear models. Pseudo-observations for mean restricted life,
as defined by Andersen, Hansen, and Klein, are created using marginal estimates of restricted mean life;
that is, O˛0 D OEŒmin.; T / D
R 
0
OP .T > t/dt , where T denotes the failure time,  is the upper limit of a
time window of interest, and OP .T > t/ is the KM estimate. Then, the pseudo-observation (PO) for each
individual, also known from jackknife methodology, is calculated as
n O˛0  .n  1/ O˛i0 ; (1)
where O˛i0 D
R 
0
OP i .T > t/dt with OP i .T > t/, the KM estimate based on data leaving out patient i .
The intuition behind POs given in (1) is that any nonparametric estimator of ˛0 D EŒmin.; T / is
also implicitly an estimator of
EZ ŒEŒmin.; T /jZ; (2)
where the inner expectation is of interest in regression modeling. In the case where the outer-
most expectation is viewed with respect to the empirical distribution of Z, with Q˛0 D 1n
Pn
iD1
EŒmin.; T /jZi , POs take the form n Q˛0  .n  1/ Q˛i0 D nŒ 1n
Pn
iD1 EŒmin.; T /jZi   .n  1/
Œ 1
n1
Pn
jD1;j¤i EŒmin.; T /jZj  D EŒmin.; T /jZi , the quantity of interest in regression modeling.
Andersen, Hansen, and Klein make the case that O˛0 and Q˛0 are both consistent for ˛0; hence, POs based
on (1), which are estimable from censored data, can be used to estimate regression parameters predicting
EŒmin.; T /jZi  by using readily available linear models. That is, models based on individual specific
POs in (1), i D 1; : : : ; n will have regression parameters similar to a model fit to min.; T / values,
i D 1; : : : ; n, if these values were available (uncensored). Graw et al. [8] formalize this argument and
verify appropriate asymptotics of parametric estimates.
Any modeling strategy for estimating restricted means requires taking into account an especially
interesting dependent censoring issue when updating the LAS to a more current cohort of patients. By
removing more urgent patients from the waiting list to get transplanted (via the LAS), our resulting anal-
ysis data set is dependently censored in direct relationship to daily changing LAS of individual patients.
In considering a restricted mean model approach, KM estimates used in creating POs are especially
subject to dependent censoring bias. Inverse probability of censoring weighted (IPCW) methods, such
as those discussed by Robins and Finkelstein [9], Robins [10], Robins and Rotnitzky [11], Satten et al.
[12], and Scharfstein et al. [13] among others, have been successful in counteracting this type of bias
and can be used to consistently estimate ST .t/ D P.T > t/, cumulative hazard functions, and other
quantities of interest.
In this paper, we propose to estimate transplant urgency and benefit by using a PO approach to esti-
mate 1-year restricted mean life separately in wait list and post-transplant cohorts. Our approach will
modify each wait list restricted mean PO by including IPCW-based survival estimates in place of KM
estimates to account for dependent censoring linked to time-dependent LAS of patients. We will esti-
mate a 1-year transplant benefit for each patient by using a restricted mean model estimate of days lived
in a year following transplant minus a separate restricted mean model estimate of days lived in a year
following listing without transplant.
We structure the rest of the manuscript as follows. In Section 2, we formally describe the mean struc-
ture for restricted life given covariates, an appropriate PO approach to fit this mean structure, and the
IPCW implementation of POs required to account for censoring via time-dependent LAS. Section 3
briefly shows simulation studies that ensure that our overall analysis approach in the presence of depen-
dent censoring is sound in finite sample populations. In Section 4, we present a restricted mean model
for lung wait list candidates and separately for post-transplant recipients to be used in constructing an
LAS for each patient. We provide results on estimated days of life without transplant in a 1-year period
(urgency) as well as estimated days gained from transplant over the following 1-year period (benefit).
We also display estimated LAS for lung transplant candidates by using the new methodology and also
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provide results by using estimates of restricted means for lung candidates based on integrating both
traditional and IPCW-adjusted Cox PH model survival curves. Discussion follows in Section 5.
2. Estimating restricted mean life by using inverse probability of censoring
weighted pseudo-observation
2.1. Mean structure for restricted mean life
The mean structure for the restricted mean life is
EŒlogfmin.; T /g D ˇT Z; (3)
where  is fixed and is within the range of the observed data. When there is no censoring, uncensored
data applied to model (3) becomes a standard linear model on logfmin.; T /g. However when censoring
is present and informative, the use of observed data will lead to biased results.
Andersen et al. [7] formulated POs by using (1) and then fitted model (3) to the resulting POs by using
standard linear models. An equally appropriate approach would be to fit the model of the restricted mean
by using a log link. We have found that the intercept estimator is somewhat improved upon creating
POs based on the transformed random variable logfmin.; T /g. That is, instead of creating POs based
on O˛0 D OEŒmin.; T / D
R 
0
OS.t/dt and log transforming the pseudo-values, we will create POs based
on marginal estimates of Oı0 D OEŒlogfmin.; T /g. Let Y D logfmin.; T /g, ranging from 1 to log  .
Assume for the moment the simplest form of model (3), where EŒY  D ı0, that is, the marginal mean of
logfmin.; T /g that does not depend on any covariates. We may derive the mean of Y as follows:
E.Y / D ı0 D EŒlogfmin.; T /g D
Z 1
0
logŒmin.; T /dFT .t/
D
Z 
0
log t dFT .t/ C
Z 1

log  dFT .t/
D
Z 
0
log t d.1  ST .t// C log .1  FT .//
D 
Z 
0
log t dST .t/ C log   ST ./: (4)
2.2. Pseudo-observation approach
From Equation (4) in Section 2.1, the marginal mean of logfmin.; T /g can be estimated via
Oı0 D OE.Y / D 
Z 
0
log t d OP .T > t/ C log   OP .T > / (5)
where OP .T > t/ is some marginal survival estimate on the original time scale. In the context of depen-
dent censoring, we will describe a consistent estimate for ST .t/ in Section 2.3, OSWT .t/, that uses an
inverse weight approach and show that its use in (5) gives a consistent estimate of ı0.
Arguments justifying the use of POs in fitting (3) proceed similarly to the original justification made
for the PO approach. That is, any estimator of ı0 is implicitly an estimator of EZ ŒEŒlogfmin.; T /gjZ.
When the outermost expectation is viewed with respect to the empirical distribution of Z with Qı0 D
1
n
Pn
jD1 EŒlogfmin.; T /gjZj  and Qıi0 D 1n1
Pn
jD1;j¤i EŒlogfmin.; T /gjZj , POs, n Qı0.n1/ Qıi0 ,
reduce to EŒlogfmin.; T /gjZi , which matches in expectation the quantity that we wish to model.
Although both Qı0 and Oı0 are consistent for ı0, the latter gives the most useful form for estimating ı0
based on censored survival data. So, similar to the strategy employed on the scale of ˛0, we base our
inference on POs, n Oı0  .n  1/ Oıi0 , where Oıi0 is estimated from (5) leaving out individual i .
Once POs, PO D .PO1;PO2; : : : ;POn/ are obtained, the regression model (3) can be estimated
using PO as the response. Our parameter estimates become Oˇ D .ZT Z/1ZTPO with estimated
covariance matrix OV . Oˇ/ D O2.ZT Z/1, where O2 is computed in the usual way as .POZˇ/T .PO
Zˇ/=.n  p/ for p parameters in the model. These results can be estimated from nearly any statistical
software package once POi ; i D 1; : : : ; n are obtained.
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2.3. Inverse probability of censoring weighted estimates of survival probability
In the case of dependent censoring, care needs to be taken in estimating ST .t/. Of all the potential
methods for consistently modeling marginal survival in the presence of dependent censoring, methods
based on inverse probability censoring weights used by Robins and his coauthors are perhaps the easi-
est to apply when there are many time-dependent measures over time, so we selected that approach for
estimating S.t/ for the lung allocation data.
First, one estimates the censoring survival function at any fixed time t , denoted by OKVi .t/ D P.Ci >
t j NVi .t//, where Ci is the censoring time for patient i and NVi .t/ D fVi .u/I 0 6 u 6 tg is the patient’s
recorded history up to time t of a vector of possibly time-dependent covariates, Vi , that predict the cen-
soring time Ci . In the case of the lung allocation data, Ci is the time a patient is removed from the lung
wait list for transplant, and NVi .t/ consists of patient LAS used to rank patients for transplant from time 0
(listing time) to time t as well as a few additional predictors including race, gender, blood type, height,
and active waiting status. In calculating the contribution of a subject at risk at time t , the subject is given
a weight inversely proportional to his or her estimated probability of remaining uncensored until time t
with a history of NVi .t/, that is,
OWi .t/ D 1= OKVi .t/:
The Cox model for censoring survival is often used in inverse weighting approaches because of its
flexibility in modeling time-dependent covariates. Because time-dependent LAS is an issue in our case,
this is the approach that we adopt as well. A Cox model for the censoring hazard is given by
Qft j NV.t/g D Q0.t/ expf 0V.t/g: (6)
In the case of the lung wait list data,  0V.t/ becomes 1 LAS.t/C2 raceC3 genderC4 blood typeC
5 height C 6 I (active waiting status). Then, a consistent estimate of the probability that subject i gets
censored after time t , KVi .t/, becomes
OKVi .t/ D expf
nX
kD1
Z t
0
e O 0Vi .u/dNQk .u/Pn
jD1 Yj .u/e O
0Vj .u/
g;
where NQi D I.Xi 6 u; ıi D 0/ is the observable counting process for censoring (transplant), with Xi
as the observed event time and ıi as the censoring indicator, and Yi .u/ D I.Xi > u/ is the risk indicator
for subject i at time u. The subject-specific weight then becomes
OWi .t/ D 1= OKVi .t/ D expf
nX
kD1
Z t
0
e O 0Vi .u/dNQk .u/Pn
jD1 Yj .u/e O
0Vj .u/
g:
An IPCW version of Nelson–Aalen estimator for ƒ.t/ is calculated using
OƒW .t/ D
nX
iD1
Z t
0
dNTi .u/  OWi .u/Pn
jD1 Yj .u/  OWj .u/
;
where NTi .u/ D I.Xi 6 u; ıi D 1/ is the observable counting process for death. Then, the survival
probability is estimated with OSW .t/ D expf OƒW .t/g. The adjusted POs described in Section 2.2 use
OP .T > t/ D OSW .t/ in Equation (5). Product-integral versions of inverse weighted survival functions
such as those described by Satten and Datta [14] would also be appropriate for use as an alternative to
OSW .t/.
Proof of consistency of OSWT .t/ D exp. OƒW .t// for ST .t/ proceeds from consistency of OƒW .t/ for
ƒ.t/, a property that was studied extensively by Robins [10] and Robins and Finkelstein [9]. Conditions
required for this consistency to hold are that (i) Q.t j NV .t// follows the form given in Equation (6) and
(ii) Q.t j NV .t/; T; T > t/ D Q.t j NV .t/; T > t/. Consistency of OE.Y /, used in creating POs in this
manuscript, follows from noting that
R 
0
log t d OSWT .t/ in (5) can be written as
lim
m!1
mX
jD1
log tj M OSWT .tj /
p! lim
m!1
mX
jD1
log tj M ST .tj / D
Z 
0
log t dST .t/:
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3. Simulation study
To validate the method used in analyzing the lung candidate wait list data subjected to dependent
censoring, we conduct a simulation study comparing parameter estimates of model (3) by using lin-
ear regression when (i) logŒmin.; T / is uncensored, (ii) logŒmin.; T / is subject to censoring and is
replaced by log-transformed POs defined by (1), and (iii) logŒmin.; T / is subject to censoring and is
replaced by IPCW-adjusted POs.
In each simulation, we perform the following procedures.
Step 1: We simulate Z0 from a Bernoulli(0.5) distribution, Z1 from Bernoulli(0.5), and Z2 from
Uniform(0,1), where Z0 is a binary covariate measured at time 0, Z1 is the time-dependent
covariate measured at time t1 D 0:2, and Z2 is a continuous time-independent covariate.
Step 2: We simulate failure times, Ti , from piecewise exponential distributions; that is, Ti  exp.´0/
before time t1, and Ti  exp.´0´1/, after time t1, where 0 D 0:3 and 1 D 0:2 are
fixed and 00; 01; 10, and 11 are solved so that the mean structure EŒlogfmin.; T /g D
ˇ0 C ˇ1Z0 C ˇ2Z2 is satisfied for a pre-specified ˇ D .ˇ0; ˇ1; ˇ2/. That is, although Ti is
influenced by the time-dependent covariate, Z1, the restricted mean of interest is captured by
baseline predictors Z0 and Z2. We provide more details for these calculations in Appendix A.
Step 3: We also generate dependent censoring times Ci from piecewise exponential distributions and
obtain hazard rates based on the Cox model C .t j NZ.t// D C0 .t/ expf0Z0 C 1I ŒZ0 D
0;Z1 D 1; t > t1 C 2I ŒZ0 D 1;Z1 D 0; t > t1 C 3I ŒZ0 D 1;Z1 D 1; t > t1 C 4Z2g,
where C0 .t/ D 0:15 for t 6 t1 and C0 .t/ D 0:4 for t > t1, 0 D 0:3; 1 D 1:4; 2 D
0:5; 3 D 1:5, and 4 D 1. So, Z0; Z2, and time-dependent Z1 influence censoring.
For each scenario of ˇ, we run 1000 simulations with  D 5 years and either n D 150 or n D 300
patients. Results for the scenario with ˇ0 D 0:8; ˇ1 D ˇ2 D 0 are located in part (1) of Table I. In this
Table I. Comparison of estimates from model (3) by using uncensored observations (uncensored), the tra-
ditional pseudo-observation (PO) approach, and the inverse probability of censoring weighted (IPCW) PO
approach under two scenarios, 1000 iterations.
Parameter Uncensored PO IPCW Uncensored PO IPCW PO Uncensored PO IPCW
PO SE* SE SE ESD† ESD ESD
(1) Covariate effects are zero, sample size D 150
ˇ0 D 0:8 0.808 0.105 0.702 0.210 0.425 0.243 0.220 0.576 0.235
ˇ1 D 0 0.012 0:266 0.059 0.187 0.380 0.217 0.195 0.400 0.215
ˇ2 D 0 0:013 0.154 0:022 0.325 0.658 0.377 0.328 0.705 0.372
Covariate effects are zero, sample size D 300
ˇ0 D 0:8 0.798 0.137 0.697 0.148 0.294 0.172 0.153 0.460 0.163
ˇ1 D 0 0.001 0:296 0.049 0.132 0.263 0.154 0.134 0.281 0.155
ˇ2 D 0 0.008 0.170 0.000 0.230 0.456 0.267 0.234 0.472 0.262
(2) Covariate effects are nonzero, sample size D 150
ˇ0 D 1 0.998 0.759 0.891 0.202 0.309 0.239 0.205 0.324 0.220
ˇ1 D 0:8 0:799 1:025 0:796 0.181 0.276 0.214 0.180 0.326 0.194
ˇ2 D 0:5 0:497 0:443 0:426 0.314 0.479 0.372 0.315 0.496 0.351
Covariate effects are nonzero, sample size D 300
ˇ0 D 1 0.992 0.772 0.883 0.142 0.206 0.170 0.146 0.220 0.158
ˇ1 D 0:8 0:799 0:971 0:792 0.128 0.184 0.152 0.127 0.225 0.138
ˇ2 D 0:5 0:486 0:413 0:417 0.221 0.319 0.263 0.224 0.325 0.247
*SE is the average of estimated standard errors across 1000 iterations.
ESD is the empirical standard deviation of 1000 parameter estimates.
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case, the true baseline covariate effects on survival are zero, but dependent censoring is being driven
by the time-dependent covariate. The unadjusted PO method gives more biased estimates for all the
parameters, especially for ˇ0 and ˇ1. The IPCW-adjusted PO method reduces bias substantially and also
has smaller standard error after adjusting for dependent censoring. When both baseline covariates are
equal to 0.5, the PO method underestimates the time lived during the 5-year period by 14 months on
average whereas the IPCW PO method is off by only 2 months over the 5-year period. Empirical stan-
dard deviations were comparable with standard errors averaged across simulations, with the exception
of the intercept term for the traditional PO method. Coverage for the traditional PO intercept was 66.7%,
in spite of its much wider confidence interval width, because of the increased bias and underestimated
variability for that term.
Simulation results for the scenario with ˇ0 D 1, ˇ1 D 0:8, and ˇ2 D 0:5, that is, nonzero base-
line covariate effects, are located in part (2) of Table I. Again, bias is higher for ˇ0 and ˇ1 by using
the traditional PO, but in this case, the value for ˇ2 is largely unaffected by the dependent censoring.
The adjusted PO method has both smaller bias and smaller standard error for ˇ0 and ˇ1. The overall
degree of bias for estimating the time lived during the 5-year period was smaller in this scenario, with
the traditional PO method off by approximately 4–5 months of life lived and the IPCW PO method off
by 1 month over the 5-year period for a patient with ´0 D ´2 D 0:5.
Parameter estimates were similar for cases with n D 150 and n D 300. We were unable to explore
larger sample sizes because of limitations in computing speed, so it is not clear at what sample size
remaining bias with the IPCW PO method vanishes. Across a grid of possible covariate values for these
two scenarios, the bias for the IPCW PO method did not exceed 3.6 months over the 5 years of follow-up.
But bias as high as 16 months was seen using the unadjusted PO method.
4. Example
We organize this section into three components. Section 4.1 summarizes analyses for the lung wait
list candidates, Section 4.2 summarizes analyses for the post-transplant cohort, and Section 4.3 inter-
prets these analyses in terms of urgency, benefit, and LAS calculated for the wait list patient cohort.
Results are typically reported by the four defined diagnosis groups A, B, C, and D. Diagnosis group A
is obstructive lung disease, primarily chronic obstructive pulmonary disease. Group B consists of pul-
monary vascular diseases, primarily idiopathic pulmonary arterial hypertension. Group C consists of
cystic fibrosis, as well as immunodeficiency disorders. Group D is restrictive lung disease, primarily
interstitial pulmonary fibrosis. The OPTN Thoracic Committee classifies all lung wait list patients into
one of these four diagnosis groups for the purpose of estimating diagnosis group influence on urgency
and benefit, and modeling interactions across diagnosis groups. A few diagnoses, such as bronchiectasis,
are given a parameter to distinguish their estimated days of life from that of their overall diagnosis group.
These parameters have historically not been significantly different from those of their overall diagnosis
group, and yet patient advocates have actively pursued the ability to estimate urgency and benefit more
specifically for their patients to the extent that enough data are available to do so.
4.1. Lung candidate analysis
The wait list candidate data contain 3701 lung candidates aged 12 years and above who were newly
listed in the lung wait list during September 1, 2006 and September 30, 2008. Censoring within 1 year of
listing only occurs when a candidate is transplanted, which was the case with 2698 (73%) of the candi-
dates. By diagnosis group, 923 (70%) of 1317 group A candidates, 67 (58%) of 116 group B candidates,
294 (69%) of 428 group C candidates, and 1414 (77%) of 1840 group D candidates were transplanted.
Historically, of the four groups, diagnosis group D has had the poorest wait list survival, and with the
LAS based in part on urgency, this group also currently experiences the shortest time to transplant. The
median time to transplant for group D is only 71 days, as opposed to 170 days for group A, 221 days
for group B, and 126 days for group C. We show baseline characteristics by primary diagnosis group
in Table II. At listing, group D patients typically have very high severity and poor physiologic reserve.
In contrast, group A patients have historically had much lower urgency for transplant as measured by
survival. These patients are often seeking a transplant based on improving quality of life as opposed to
lengthening life.
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Table II. Baseline characteristics by diagnosis group for 3701 lung wait list patients.
Group A Group B Group C Group D
(primarily COPD) (primarily iPAH) (primarily CF) (primarily IPF)
Characteristics n D 1317 n D 116 n D 428 n D 1840
Physiologic reserve
Age (years) 57:6 ˙ 8:1* 45:9 ˙ 15:1 27:9 ˙ 10:3 55:9 ˙ 11:6
BMI (kg/m2) 24:6 ˙ 4:3 24:8 ˙ 4:3 19:1 ˙ 2:9 26:7 ˙ 4:6
Diabetes 11:0%† 10:3% 48:4% 22:9%
No assistance with ADL 10:4% 9:4% 20:9% 9:6%
6-min walk distance (feet) 770:5 ˙ 356:0 733:3 ˙ 480:8 902:2 ˙ 508:0 755:8 ˙ 482:0
Severity
FVC (% predicted) 52:4 ˙ 17:2 69:3 ˙ 23:1 38:1 ˙ 11:1 47:0 ˙ 16:7
O2 requirement at rest (l/min) 3:1 ˙ 2:5 4:6 ˙ 5:1 3:4 ˙ 4:1 4:6 ˙ 4:7
PA systolic (mmHg) 38:0 ˙ 10:8 78:5 ˙ 24:0 38:8 ˙ 10:6 42:9 ˙ 17:0
PCO2 (mmHg) 50:3 ˙ 11:7 43:5 ˙ 7:0 56:2 ˙ 20:0 45:9 ˙ 11:6
Continuous mechanical ventilation 1:1% 2:6% 7:5% 6:1%
Serum creatinine (mg/dl) 0:82 ˙ 0:2 0:94 ˙ 0:3 0:67 ˙ 0:2 0:91 ˙ 0:3
Cardiac index< 2:0 (l/min/min2) 5:5% 35:6% 1:6% 7:8%
*For continuous variables, the numbers shown are mean ˙ standard deviation.
For binary variables, the numbers shown are proportions.
ADL, activities of daily living; BMI, body mass index; CF, cystic fibrosis; COPD, chronic obstructive pulmonary dis-
ease; FVC, forced vital capacity; iPAH, idiopathic pulmonary arterial hypertension; IPF, interstitial pulmonary fibrosis;
PA, pulmonary artery; PCO2, partial pressure of carbon dioxide.
Table III. Proportional hazards censoring model (3701 candidates).
Parameter HR 95% CI p-value
Characteristic at listing
Female (versus male) 0.72 (0.63, 0.82) <.0001
Race: Black (versus White) 0.81 (0.68, 0.95) 0.0116
Race: Other (versus White) 0.91 (0.77, 1.08) 0.3016
Height: <50300 (versus >50900) 0.54 (0.45, 0.65) <.0001
Height: 50300 to 50600 (versus >50900) 0.73 (0.62, 0.86) 0.0001
Height: 50600 to 50900 (versus >50900) 0.80 (0.71, 0.90) 0.0001
Blood type: B (versus A) 1.06 (0.91, 1.23) 0.4801
Blood type: O (versus A) 0.92 (0.84, 1.02) 0.1118
Blood type: AB (versus A) 1.07 (0.85, 1.33) 0.5669
Time-dependent patient condition and listing status
LAS D 0 (versus LAS > 0) 0.16 .0:02; 1:18/ 0.0728
LAS: linear spline for 30C 1.12* .1:06; 1:19/ <.0001
LAS: linear spline for 35C 0.98† .0:91; 1:06/ 0.6779
LAS: linear spline for 40C 0.95‡ .0:91; 0:99/ 0.0070
LAS: linear spline for 60C 0.97§ .0:95; 0:98/ <.0001
Inactive status (versus active) 0.00 (0, >1000) 0.8780
Off the wait list (versus active) 0.00 (0, >1000) 0.9410
Inverse weights based on this model are capped at 20.
*Hazard ratio (HR) corresponding to one unit increase for lung allocation score (LAS) 30C relative to those with
0 < LAS < 30.
HR corresponding to spline term for LAS 35C, giving HR due to one unit increase in LAS in the range 35 6 LAS < 40
of 1:12  0:98 D 1:10 relative to 0 < LAS < 30.
HR corresponding to spline term for LAS 40C, giving HR due to one unit increase in LAS in the range 40 6 LAS < 60
of 1:12  0:98  0:95 D 1:04 relative to 0 < LAS < 30.
HR corresponding to spline term for LAS 60C, giving HR due to one unit increase in LAS in the range LAS > 60 of
1:12  0:98  0:95  0:97 D 1:01 relative to 0 < LAS < 30.
We use the P(censoring occurs after time t jcandidate’s history up to and including t ) to calculate
an inverse weight used in consistent estimation of survival curves and adjusted POs as described in
Sections 2.2 and 2.3. In particular, we use a time-dependent Cox model for time to censoring, which
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includes patients’ daily updated LAS, gender, race, blood type, status (active, inactive, offlist), and
height, as given in Equation (6). We summarize parameter estimates from the Cox model on the cen-
soring hazard in Table III. Probability of transplant is strongly influenced by current LAS values.
Although one might expect the probability of transplant to increase monotonically as current LAS
increases, in fact, the higher transplant priority is tempered by a lower chance of surviving until an
organ becomes available for those with the highest LAS values. This feature is reflected in the parameter
estimates shown.
To estimate lung candidate urgency, we fit model (3) by using both IPCW-adjusted POs and tradi-
tional POs. For comparison, we estimate restricted means for lung candidates by integrating traditional
and IPCW-adjusted survival curves based on Cox model [6]. Predictors included in all lung candidate
models are the same as those proposed by the OPTN Thoracic Committee in modeling wait list sur-
vival for this cohort [15]. The Thoracic Committee has vetted extensively all predictors as being worthy
of inclusion in the algorithm based on statistical and/or clinical validity based on either the current or
Table IV. Lung wait list results for model (3) by using IPCW PO and traditional PO methods for 3701 lung
candidates.
IPCW PO Traditional PO
e
Oˇ
* 95% CI p-value e Oˇ 95% CI p-value
(Intercept) 102.15 (15.96, 653.55) <0.0001 301.71 (162.16, 561.37) <0.0001
Diagnosis group (ref D group A, primarily COPD)
Group B (primarily iPAH) 0.19 (0.05, 0.73) 0.0158 0.25 (0.16, 0.39) <0.0001
Group C (primarily CF) 0.57 (0.17, 1.90) 0.3627 0.56 (0.38, 0.84) 0.0047
Group D (primarily IPF) 0.11 (0.03, 0.38) 0.0004 0.40 (0.27, 0.60) <0.0001
Diagnosis†
Bronchiectasis 0.76 (0.21, 2.72) 0.6694 0.98 (0.64, 1.50) 0.9230
Lymphangioleiomyomatosis 1.25 (0.10, 16.41) 0.8639 0.93 (0.39, 2.20) 0.8711
Obliterativebronchiolitis 0.25 (0.03, 1.86) 0.1744 1.61 (0.82, 3.17) 0.1667
Pulmonary fibrosis other 0.77 (0.37, 1.59) 0.4741 1.04 (0.82, 1.33) 0.7445
Sarcoidosis and PA mean >30 mmHg 0.46 (0.16, 1.37) 0.1641 1.37 (0.95, 1.97) 0.0910
Sarcoidosis and PA mean 630 mmHg 0.84 (0.22, 3.13) 0.7893 0.64 (0.41, 1.00) 0.0480
Physiologic reserve
Age (years) 1.00 (0.98, 1.02) 0.9919 1.00 (1.00, 1.01) 0.8456
BMI (kg/m2) 1.07 (1.03, 1.11) 0.0011 1.03 (1.01, 1.04) 0.0001
Diabetes 0.49 (0.33, 0.73) 0.0005 0.92 (0.80, 1.05) 0.2131
No assistance with ADL 1.08 (0.65, 1.80) 0.7609 1.00 (0.85, 1.19) 0.9642
(ref D some/total assistance with ADL)
6-min walk (per 100 ft) 1.07 (1.03, 1.12) 0.0012 1.04 (1.02, 1.05) <0.0001
Severity
FVC for group D 1.25 (1.08, 1.43) 0.0019 1.06 (1.01, 1.11) 0.0243
(per 10% predicted)
O2 requirement for groups A, C, and D 0.87 (0.83, 0.91) <0.0001 0.92 (0.90, 0.93) <0.0001
(l/min)
PA systolic (per 10 mmHg) for group A 0.91 (0.71, 1.16) 0.4331 0.94 (0.87, 1.02) 0.1613
PCO2 increase of >15% 1.03 (0.41, 2.59) 0.9449 1.00 (0.73, 1.36) 0.9889
PCO2 (mmHg) 1.00 (0.99, 1.02) 0.6560 0.99 (0.99, 1.00) 0.0068
Continuous mechanical ventilation 0.07 (0.03, 0.20) <0.0001 0.13 (0.10, 0.18) <0.0001
Creatinine (mg/dl) 0.60 (0.32, 1.12) 0.1111 0.91 (0.74, 1.13) 0.3999
Cardiac index <2.0 (l/min/min2) 0.48 (0.25, 0.94) 0.0315 0.62 (0.50, 0.77) <0.0001
*For risk factors, e Oˇ acts multiplicatively on the number of days lived in a year.
†The OPTN Thoracic Committee grouped these diagnoses into larger diagnosis groups (A, B, C, and D) for the purpose
of modeling risk factors that may vary by diagnosis group. Bronchiectasis, lymphangioleiomyomatosis, and sarcoidosid
and PA mean 630 mmHg share risk factor parameters with diagnosis group A; Eisenmenger with group B; and obliter-
ativebronchiolitis, pulmonary fibrosis other, and sarcoidosis and PA mean >30 mmHg with group D.
ADL, activities of daily living; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; FVC, forced
vital capacity; iPAH, idiopathic pulmonary arterial hypertension; IPCW PO, inverse probability of censoring
weighted pseudo-observation; IPF, interstitial pulmonary fibrosis; PA, pulmonary artery; PCO2, partial pressure of
carbon dioxide.
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a prior wait list cohort studied. In some cases, statistically insignificant parameters are maintained as
placeholders with the expectation that statistical significance will re-assert itself in future cohorts; age,
assistance with ADL, PA systolic, PCO2, and creatinine fall into this category. With many fewer wait
list deaths available for modeling purposes after LAS implementation, loss of statistical power has also
been cited as an argument for maintaining a predictor in the LAS that has previously been shown to be
statistically significant.
We show parameter estimates for fitting model (3) to patients awaiting transplant in Table IV. For
risk factors, e Oˇ acts multiplicatively on the number of days lived in a year. For instance, the estimated
number of days lived is 102:150:111:07250:491:0731:255:50:8720:600:8 D 63 days based
on IPCW PO and 301:710:401:0325 0:921:043 1:065:5 0:922 0:910:8 D 283 days based on
traditional PO for a 55-year-old diagnosis group D patient who has a BMI of 25, has diabetes, requires
assistance with ADL, walks 300 ft in 6 min, has 55% predicted FVC, requires 2 l/min of O2 at rest, is
not on a ventilator, has a stable creatinine of 0.8 mg/dl, has no partial pressure of CO2 in their blood,
and has a cardiac index >2 l/min/min2. So, the unadjusted PO overestimates the number of days lived
in the next year without transplant by 220 days for this very urgent group D patient. We show estimated
KM and IPCW survival curves used in PO calculations in Figure 2; overestimation of days lived using
the traditional PO model stems from the overestimation of survival by the KM method.
We show traditional and IPCW-adjusted Cox model hazard ratios estimated from the lung candidate
data in Table V. The difference in area under the baseline survival curves over a year for the two meth-
ods was 11 days, with a more favorable survival profile without adjustment. Integrating a survival curve
estimated from a traditional Cox PH model for this patient yields an estimated number of days lived of
330, which exceeds the estimate based on the unadjusted PO model. The IPCW-adjusted Cox model esti-
mates a restricted mean of 301 for the same patient. Because bias due to dependent censoring has been
accounted for in both IPCW PO method and IPCW Cox method, different modeling restrictions account
for the observed differences in estimation. We provide additional information on urgency estimates based
on different modeling paradigms in Section 4.3.
4.2. Lung recipient analysis
The post-transplant data contain 4784 patients aged 12 years and above who received a lung transplant
between May 4, 2005 and September 3, 2008. One-year event rates from the time of transplant are per-
fectly known, that is, no censoring, with 816 (17%) deaths within the first year. We show results from
fitting model (3) in the uncensored case in Table VI. For the same group D wait list patient described in
Section 4.1, the estimated days lived in the first year following transplant is 254 days based on the model
in Table VI. Recall that the estimated days gained in the first year following transplant is calculated
using the estimated days lived 1 year post-transplant as in Section 4.2 minus the estimated days lived
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Figure 2. Wait list survival probabilities estimated using KM and IPCW.
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Table V. Lung wait list survival model by using IPCW Cox and traditional Cox methods for 3701 lung
candidates.
Hazard IPCW Cox Hazard Traditional Cox
ratio 95% CI p-value ratio 95% CI p-value
Diagnosis group (ref D group A, primarily COPD)
Group B (primarily iPAH) 2.75 (1.70, 4.45) <.0001 2.47 (1.78, 3.44) <.0001
Group C (primarily CF) 1.65 (1.05, 2.59) 0.0299 1.46 (1.09, 1.95) 0.0105
Group D (primarily IPF) 2.58 (1.56, 4.27) 0.0002 2.39 (1.75, 3.25) <.0001
Diagnosis*
Bronchiectasis 1.27 (0.78, 2.10) 0.3381 1.19 (0.86, 1.65) 0.3027
Lymphangioleiomyomatosis 1.10 (0.40, 2.98) 0.8529 0.93 (0.44, 1.93) 0.8358
Obliterativebronchiolitis 0.61 (0.19, 1.90) 0.3917 1.39 (0.89, 2.16) 0.1429
Pulmonary fibrosis other 1.07 (0.78, 1.49) 0.6673 0.80 (0.67, 0.96) 0.0180
Sarcoidosis and PA mean >30 mmHg 0.72 (0.49, 1.07) 0.1063 0.89 (0.73, 1.10) 0.2803
Sarcoidosis and PA mean 630 mmHg 1.25 (0.80, 1.96) 0.3292 1.03 (0.76, 1.39) 0.8513
Physiologic reserve
Age (years) 1.00 (1.00, 1.01) 0.6546 1.00 (1.00, 1.01) 0.4194
BMI (kg/m2) 0.98 (0.97, 1.00) 0.0428 0.97 (0.96, 0.98) <.0001
Diabetes 1.23 (1.04, 1.44) 0.0144 1.38 (1.25, 1.52) <.0001
No assistance with ADL 1.00 (0.82, 1.21) 0.9987 1.00 (0.88, 1.14) 0.9882
(ref D some/total assistance with ADL)
6-min walk (per 100 ft) 0.97 (0.95, 0.98) 0.0001 0.97 (0.96, 0.98) <.0001
Severity
FVC for group D 0.93 .0:87; 0:99/ 0.0161 0.94 (0.90, 0.97) 0.0005
(per 10% predicted)
O2 requirement for groups A, C, and D 1.11 (1.09, 1.13) <.0001 1.10 (1.09, 1.11) <.0001
(l/min)
PA systolic (per 10 mmHg) for group A 1.04 (0.94, 1.14) 0.4304 1.05 (0.99, 1.12) 0.0924
PCO2 increase of >15% 1.13 (0.79, 1.62) 0.5023 1.38 (1.08, 1.75) 0.0095
PCO2 (mmHg) 1.01 (1.01, 1.02) <.0001 1.01 (1.01, 1.01) <.0001
Continuous mechanical ventilation 5.59 (4.08, 7.66) <.0001 4.29 (3.49, 5.28) <.0001
Creatinine (mg/dl) 1.57 (1.23, 2.01) 0.0003 1.68 (1.43, 1.98) <.0001
Cardiac index <2.0 (l/min/min2) 1.36 (1.07, 1.73) 0.0128 1.30 (1.11, 1.52) 0.0010
The OPTN Thoracic Committee grouped these diagnoses into larger diagnosis groups (A, B, C, and D) for the purpose
of modeling risk factors that may vary by diagnosis group. Bronchiectasis, lymphangioleiomyomatosis, and sarcoidosid
and PA mean 630 mmHg share risk factor parameters with diagnosis group A; Eisenmenger with group B; and obliter-
ativebronchiolitis, pulmonary fibrosis other, and sarcoidosis and PA mean >30 mmHg with group D.
ADL, activities of daily living; BMI, body mass index; CF, cystic fibrosis; COPD, chronic obstructive pulmonary dis-
ease; FVC, forced vital capacity; iPAH, idiopathic pulmonary arterial hypertension; IPCW PO, inverse probability
of censoring weighted pseudo-observation; IPF, interstitial pulmonary fibrosis; PA, pulmonary artery; PCO2, partial
pressure of carbon dioxide.
1 year without transplant as in Section 4.1. So, the IPCW PO method estimates 254  63 D 191 days
gained during the first year after a transplant for this patient. All other methods indicate days of life lost
if transplanted. The IPCW Cox method, the traditional PO method, and the unadjusted Cox method give
254  301 D 47 days, 254  283 D 29 days, and 254  330 D 76 days, respectively.
4.3. Urgency, benefit, and lung allocation scores
Figure 3 shows boxplots of estimated transplant urgency for the 3701 wait listed patients by diagnosis
group, using the two PO modeling paradigms laid out in Table IV and the two Cox modeling paradigms
in Table V. By adjusting for dependent censoring, POs based on IPCW survival curves estimated a higher
urgency in group D patients, which better matches group D survival experience seen before organ allo-
cation took urgency into account (i.e., before LAS-induced dependent censoring was introduced). The
integrated IPCW Cox survival curves also show more urgency than the integrated Cox survival curves
that do not take into account dependent censoring. The interquartile range for urgency estimates based
on integrated Cox PH survival curves is decidedly more narrow than the range of estimated restricted
means based on model 3 for either the PO or the IPCW PO methods. In addition, the Cox modeling
approaches tend to estimate many more days lived without transplant compared with the PO methods.
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 561–576
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Table VI. Lung post-transplant results for model (3) for 4784 transplant recipients (no censored data).
e
Oˇ
* 95% CI p-value
(Intercept) 344.42 (303.36, 391.03) <0.0001
Diagnosis group (ref D group A, primarily COPD)
Group B (primarily iPAH) 0.65 (0.52, 0.81) 0.0002
Group C (primarily CF) 0.92 (0.82, 1.04) 0.1713
Group D (primarily IPF) 0.84 (0.73, 0.96) 0.0107
Diagnosis†
Bronchiectasis 0.96 (0.78, 1.17) 0.6796
Eisenmenger 0.32 (0.11, 0.91) 0.0331
Lymphangioleiomyomatosis 1.24 (0.89, 1.74) 0.2060
Obliterativebronchiolitis 1.25 (0.93, 1.69) 0.1437
Pulmonary Fibrosis other 1.01 (0.89, 1.15) 0.8734
Sarcoidosis and PA mean >30 mmHg 0.90 (0.74, 1.08) 0.2561
Sarcoidosis and PA mean 630 mmHg 1.00 (0.79, 1.26) 0.9927
Physiologic reserve
Age > 45 spline‡ (years) 0.99 (0.99, 1.00) 0.0139
No assistance with ADL 1.02 (0.94, 1.11) 0.6648
6-min walk (per 100 ft) 1.01 (1.01, 1.02) 0.0002
Severity
Creatinine at transplant (mg/dl) 0.89 (0.83, 0.96) 0.0017
FVC for dgn groups B and D (per 10% predicted) 1.01 (0.99, 1.03) 0.4567
Continuous mechanical ventilation at transplant 0.72 (0.63, 0.83) <0.0001
Cardiac index <2.0 (l/min/min2) 0.86 (0.74, 1.00) 0.0496
O2 at rest for dgn group A (l/min) 0.97 (0.96, 0.99) 0.0063
O2 at rest for dgn groups B, C, and D (l/min) 0.99 (0.98, 1.00) 0.2129
Change in creatinine >150% 0.78 (0.65, 0.95) 0.0132
*For risk factors, e Oˇ acts multiplicatively on the number of days lived in a year.
The OPTN Thoracic Committee grouped these diagnoses into larger diagnosis groups (A, B, C, and D) for the
purpose of modeling risk factors that may vary by diagnosis group. Bronchiectasis, lymphangioleiomyomatosis, and
sarcoidosid and PA mean 630 mmHg share risk factor parameters with diagnosis group A; Eisenmenger with group B;
and obliterativebronchiolitis, pulmonary fibrosis other, and sarcoidosis and PA mean >30 mmHg with group D.
Age >45 spline: the maximum of 0 and age 45.
ADL, activities of daily living; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; FVC, forced vital
capacity; iPAH, idiopathic pulmonary arterial hypertension; IPF, interstitial pulmonary fibrosis; PA, pulmonary artery;
PCO2, partial pressure of carbon dioxide.
Figure 3. Urgency by diagnosis group.
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Transplant benefit calculations similar to those carried out for the hypothetical group D wait list patient
described in Sections 4.1 and 4.2 were performed for all 3701 patients in our wait list cohort. Figure 4
shows boxplots of estimated transplant benefit by diagnosis group by using IPCW PO, traditional PO,
integrated IPCW Cox PH survival, and integrated Cox PH survival for this cohort. In each case, the
lung recipient model used model (3) applied to the original (perfectly observed) data for this setting.
Patient transplant benefit calculations incorporating the IPCW PO model for urgency identified more
benefit in group D patients than when using any other modeling paradigm. The use of integrated IPCW
Cox survival curves also exhibit more estimated benefits than the use of integrated Cox survival curves
not adjusting for dependent censoring. However, benefit estimates remain low, with tight interquartile
ranges, when compared with either of the PO methods.
Figure 5(a) shows scatter plots of LAS calculated using IPCW PO versus traditional PO by diag-
nosis group, with a 45ı line superimposed on the plot. For each diagnosis group, the LAS changes
substantially when taking into account dependent censoring. When looking at the top 100 ranked patients
based on their IPCW PO derived LAS, their scores estimated using traditional PO methods dropped by
approximately 16 points on average (0.8 standard deviations of the estimated LAS distribution) when
not adjusting for dependent censoring. Similarly, scores dropped by approximately 36 points on aver-
age using the traditional Cox model integrated wait list survival curves. Model paradigm selection and
adjustment for dependent censoring have a serious impact on time to transplant for those top priority
candidates identified using IPCW PO methodology. Figure 5(b) shows a scatter plot of LAS values
when calculated using the IPCW PO method versus using integrated IPCW Cox survival curves for
wait list urgency. Circled values represent patients who would move from having a low allocation pri-
ority by using PH assumptions to a very high allocation priority by using model (3). We rank only 30
patients in the top 100 scores regardless of the IPCW method used, IPCW PO or IPCW Cox integrated
survival curves.
5. Discussion
We present new methodology for estimating restricted means in the presence of dependent censoring
captured by longitudinal covariates. Upon estimation of ST .t/ by using inverse weight methodology,
remaining inference becomes very straight forward using our suggested approach. In particular, it is not
necessary to program complicated variances of inverse weighted estimates, because the PO approach
Figure 4. Estimated transplant benefit at time of listing by diagnosis group and estimation method for 3701 lung
transplant candidates.
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(a) IPCW PO vs. PO
(b) IPCW PO vs. IPCW Cox
Figure 5. LAS at listing calculated using IPCW PO, PO, and Cox PH model by diagnosis group for 3701
lung candidates.
merges nicely into use of more standard software package for regression in evaluating parameter
estimates. Hence, this approach can realistically be implemented by statistical practitioners.
Statistical input into properly modeling components of the LAS in the USA has high impact on per-
haps 1000 patients at any given time, as the rate of new listings and wait list removals seems to balance
at that level. The success of devising and maintaining an intelligent and practical allocation system
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for urgent patients introduces a uniquely interesting set of statistical issues. Defining 1-year transplant
urgency and benefit at the individual level can be achieved successfully using our described methodol-
ogy, even when subjected to dependent censoring by transplant for more urgent patients. Hence, the LAS
can be updated now and in the future using the most recent cohort of patients with minimal bias.
When applied to the lung candidate data, the IPCW PO method gives a broader range of urgency
estimates than when estimating urgency based on integrated IPCW Cox model survival curves. This in
turn leads to a broader range of LAS values with which to prioritize the candidates. Our feeling is that
parameterization on the scale of the restricted mean leads to more appropriate urgency estimates than
parameterization based on constant hazard ratios over time, particularly after viewing the range of scores
from using different modeling paradigms in Figure 5(b).
Availability of this methodology also opens up the important possibility of adding new predictors to
the LAS, as these are identified as relevant by the transplant community and collected on OPTN lung
transplant candidates. The LAS is the first organ allocation system to explicitly order patients by both
estimated urgency and transplant benefit, although liver allocation introduced an urgency score in prior-
itizing patients around the same time the LAS was developed. No OPTN organ allocation committees
have yet updated their algorithms with adjustment for dependent censoring in more recent cohorts of
patients. Hence, this type of analysis could be applied to other allocation settings with similar dependent
censoring issues as well.
APPENDIX A.
In Section 3, we simulate settings when dependent censoring affects estimation of (3) unless adjustments
are made via the IPCW PO method. The survival function for piecewise exponential failure times used
in Section 3 is
ST .t/ D

eZ0 t 0 6 t 6 t1
eZ0 t1eZ0Z1 .tt1/ t > t1 ;
with pdf
fT .t/ D

Z0  eZ0 t 0 6 t 6 t1
Z0Z1  e.Z0Z0Z1 /t1  eZ0Z1 t t > t1 :
In step 2 of Section 3, parameters 0 D 0:3, 1 D 0:2, 01 D 0:1, and 11 D 0:5 are fixed. The
remaining parameters 00 and 10 are chosen to satisfy (3) as described in the succeeding equation.
Recall that Z1 is measured at time t1 D 0:2 and that  D 5. Also, Z0 and Z1 are generated from
independent Bernoulli(0.5).
EŒlogfmin.; T /g
DEEŒlogfmin.; T /gjZ1
D
X
´1
P.Z1 D ´1/EŒlogfmin.; T /gjZ1 D ´1
D0:5EŒlogfmin.; T /gjZ1 D 0 C 0:5EŒlogfmin.; T /gjZ1 D 1
When Z0 D 0, we have
EŒlogfmin.; T /g
D 0:5
Z t1
0
log t  0e0tdt C
Z 
t1
log t  00  e.000/t1  e00tdt C log   e0t1  e00.t1/

C 0:5
Z t1
0
log t  0e0tdt C
Z 
t1
log t  01  e.001/t1  e01tdt C log   e0t1  e01.t1/

Dˇ0 C ˇ2Z2
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We solve the aforementioned equation for 00. Similarly, when Z0 D 1, we solve the following equation
for 10:
EŒlogfmin.; T /g
D 0:5
Z t1
0
log t  1e1tdt C
Z 
t1
log t  10  e.110/t1  e10tdt C log   e1t1  e10.t1/

C 0:5
Z t1
0
log t  1e1tdt C
Z 
t1
log t  11  e.111/t1  e11tdt C log   e1t1  e11.t1/

Dˇ0 C ˇ1 C ˇ2Z2
The resulting parameters 00 and 10 vary according to the values of Z2 for patient i , i D 1; : : : ; n.
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